ALDURAZYME J Code: J1931
Injection, laronidase, 0.1 mg
Q4 2026 Medicare Payment Limit for J1931, effective October 1, 2026: $41.498 per HCPCS billing unit, unchanged from Q3 2026. From CMS's final file.
Drug & Product Overview
About ALDURAZYME
Aldurazyme is a medication aligned to the HCPCS J Code: J1931 for billing, pricing, and reimbursement purposes in the United States. Classified under Enzyme Replacement Therapy, it is administered via the intravenous route and manufactured by Genzyme.
According to CMS Drug Use Information: Laronidase is used to treat a certain rare genetic problem (mucopolysaccharidosis-MPS I). It works by replacing a certain natural substance (lysosomal enzyme) that is missing in people with this genetic problem. This medication improves lung function and how far you can walk. Laronidase is not a cure and treatment must be continued for life.
Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.
NDC Code Information
Based on publicly available CMS files. The list of NDCs below is not exhaustive.
| NDC Code | Drug | Manufacturer | Billing Units / Pkg | Package Size |
|---|---|---|---|---|
| 58468-0070-01 | Aldurazyme | Genzyme Corporation | 29 | 2.9 MG / 5 ML |
ALDURAZYME Pricing & Reimbursement
National median reimbursement across major commercial payers.
Create an account on PayerPrice for more information →Historical Graphing and Billing Calculator
Log in to calculate billing and reimbursement with live ASP, WAC & AWP pricing.
Login to use the calculator →ALDURAZYME CPT Administration Codes
The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.
| CPT Code | Description |
|---|---|
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) |
CMS has identified Aldurazyme (J1931) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →
ALDURAZYME Medically Unlikely Edits (MUE)
The most billing units of J1931 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 0.1 mg.
MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →
ALDURAZYME Clinical Information
Indications and drug classification.
This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.
Login for BuyandBill.com Analytics
Unlock deeper insights with BuyandBill’s Comparative Report!
- Compare ASP, WAC, and AWP across drugs.
- Visualize Drug Price Movement Over Time
- Tailor reports to drug class, manufacturer, or HCPCS Code.
- Compare Biosimilar and 505(b)(2) products.
Frequently Asked Questions
Is there an available Aldurazyme billing and coding guide?
Are there any available Aldurazyme patient assistance programs?
Where can I find Aldurazyme prescribing information?
Where can I find Aldurazyme side effect information?
Does billing ALDURAZYME require JZ/JW wastage modifiers?
About BuyandBill.com:
The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.
Related Drug Codes
Explore billing, coding, and pricing for drugs related to ALDURAZYME.